High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation
Background: High-throughput non-invasive prenatal testing (NIPT) for fetal rhesus (D antigen) (RhD) status could avoid unnecessary treatment with routine anti-D immunoglobulin for RhD-negative women carrying a RhD-negative fetus, although this may lead to an increased risk of RhD sensitisations. Obj...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
NIHR Journals Library
2018-03-01
|
Series: | Health Technology Assessment |
Online Access: | https://doi.org/10.3310/hta22130 |
id |
doaj-f0d61fe2bf964e9bbf0ffed947277ced |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pedro Saramago Huiqin Yang Alexis Llewellyn Ruth Walker Melissa Harden Stephen Palmer Susan Griffin Mark Simmonds |
spellingShingle |
Pedro Saramago Huiqin Yang Alexis Llewellyn Ruth Walker Melissa Harden Stephen Palmer Susan Griffin Mark Simmonds High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation Health Technology Assessment |
author_facet |
Pedro Saramago Huiqin Yang Alexis Llewellyn Ruth Walker Melissa Harden Stephen Palmer Susan Griffin Mark Simmonds |
author_sort |
Pedro Saramago |
title |
High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation |
title_short |
High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation |
title_full |
High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation |
title_fullStr |
High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation |
title_full_unstemmed |
High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation |
title_sort |
high-throughput non-invasive prenatal testing for fetal rhesus d status in rhd-negative women not known to be sensitised to the rhd antigen: a systematic review and economic evaluation |
publisher |
NIHR Journals Library |
series |
Health Technology Assessment |
issn |
1366-5278 2046-4924 |
publishDate |
2018-03-01 |
description |
Background: High-throughput non-invasive prenatal testing (NIPT) for fetal rhesus (D antigen) (RhD) status could avoid unnecessary treatment with routine anti-D immunoglobulin for RhD-negative women carrying a RhD-negative fetus, although this may lead to an increased risk of RhD sensitisations. Objectives: To systematically review the evidence on the diagnostic accuracy, clinical effectiveness and implementation of high-throughput NIPT and to develop a cost-effectiveness model. Methods: We searched MEDLINE and other databases, from inception to February 2016, for studies of high-throughput NIPT free-cell fetal deoxyribonucleic acid (DNA) tests of maternal plasma to determine fetal RhD status in RhD-negative pregnant women who were not known to be sensitised to the RhD antigen. Study quality was assessed with the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) and A Cochrane Risk of Bias Assessment Tool: for Non-Randomised Studies of Interventions (ACROBAT-NRSI). Summary estimates of false-positive rates (FPRs) and false-negative rates (FNRs) were calculated using bivariate models. Clinical effectiveness evidence was used to conduct a simulation study. We developed a de novo probabilistic decision tree-based cohort model that considered four alternative ways in which the results of NIPT could guide the use of anti-D immunoglobulin antenatally and post partum. Sensitivity analyses (SAs) were conducted to address key uncertainties and model assumptions. Results: Eight studies were included in the diagnostic accuracy review, seven studies were included in the clinical effectiveness review and 12 studies were included in the review of implementation. Meta-analyses included women mostly at or post 11 weeks’ gestation. The pooled FNR (women at risk of sensitisation) was 0.34% [95% confidence interval (CI) 0.15% to 0.76%] and the pooled FPR (women needlessly receiving anti-D) was 3.86% (95% CI 2.54% to 5.82%). SAs did not materially alter the overall results. Data on clinical outcomes, including sensitisation rates, were limited. Our simulation suggests that NIPT could substantially reduce unnecessary use of antenatal anti-D with only a small increase in the risk of sensitisation. All large implementation studies suggested that large-scale implementation of high-throughput NIPT was feasible. Seven cost-effectiveness studies were included in the review, which found that the potential for the use of NIPT to produce cost savings was dependent on the cost of the test. Our de novo model suggested that high-throughput NIPT is likely to be cost saving compared with the current practice of providing routine antenatal anti-D prophylaxis to all women who are RhD negative. The extent of the cost saving appeared to be sufficient to outweigh the small increase in sensitisations. However, the magnitude of the cost saving is highly sensitive to the cost of NIPT itself. Limitations: There was very limited evidence relating to the clinical effectiveness of high-throughput NIPT, with no evidence on potential adverse effects. The generalisability of the findings to non-white women and multiple pregnancies is unclear. Conclusions: High-throughput NIPT is sufficiently accurate to detect fetal RhD status in RhD-negative women from 11 weeks’ gestation and would considerably reduce unnecessary treatment with routine anti-D immunoglobulin, potentially resulting in cost savings of between £485,000 and £671,000 per 100,000 pregnancies if the cost of implementing NIPT is in line with that reflected in this evaluation. Future work: Further research on the diagnostic accuracy of NIPT in non-white women is needed. Study registration: This study is registered as PROSPERO CRD42015029497. Funding: The National Institute for Health Research Health Technology Assessment programme. |
url |
https://doi.org/10.3310/hta22130 |
work_keys_str_mv |
AT pedrosaramago highthroughputnoninvasiveprenataltestingforfetalrhesusdstatusinrhdnegativewomennotknowntobesensitisedtotherhdantigenasystematicreviewandeconomicevaluation AT huiqinyang highthroughputnoninvasiveprenataltestingforfetalrhesusdstatusinrhdnegativewomennotknowntobesensitisedtotherhdantigenasystematicreviewandeconomicevaluation AT alexisllewellyn highthroughputnoninvasiveprenataltestingforfetalrhesusdstatusinrhdnegativewomennotknowntobesensitisedtotherhdantigenasystematicreviewandeconomicevaluation AT ruthwalker highthroughputnoninvasiveprenataltestingforfetalrhesusdstatusinrhdnegativewomennotknowntobesensitisedtotherhdantigenasystematicreviewandeconomicevaluation AT melissaharden highthroughputnoninvasiveprenataltestingforfetalrhesusdstatusinrhdnegativewomennotknowntobesensitisedtotherhdantigenasystematicreviewandeconomicevaluation AT stephenpalmer highthroughputnoninvasiveprenataltestingforfetalrhesusdstatusinrhdnegativewomennotknowntobesensitisedtotherhdantigenasystematicreviewandeconomicevaluation AT susangriffin highthroughputnoninvasiveprenataltestingforfetalrhesusdstatusinrhdnegativewomennotknowntobesensitisedtotherhdantigenasystematicreviewandeconomicevaluation AT marksimmonds highthroughputnoninvasiveprenataltestingforfetalrhesusdstatusinrhdnegativewomennotknowntobesensitisedtotherhdantigenasystematicreviewandeconomicevaluation |
_version_ |
1725307158662217728 |
spelling |
doaj-f0d61fe2bf964e9bbf0ffed947277ced2020-11-25T00:35:54ZengNIHR Journals LibraryHealth Technology Assessment1366-52782046-49242018-03-01221310.3310/hta2213015/17/02High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluationPedro Saramago0Huiqin Yang1Alexis Llewellyn2Ruth Walker3Melissa Harden4Stephen Palmer5Susan Griffin6Mark Simmonds7Centre for Health Economics, University of York, York, UKPeninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UKCentre for Reviews and Dissemination, University of York, York, UKCentre for Reviews and Dissemination, University of York, York, UKCentre for Reviews and Dissemination, University of York, York, UKCentre for Health Economics, University of York, York, UKCentre for Health Economics, University of York, York, UKCentre for Reviews and Dissemination, University of York, York, UKBackground: High-throughput non-invasive prenatal testing (NIPT) for fetal rhesus (D antigen) (RhD) status could avoid unnecessary treatment with routine anti-D immunoglobulin for RhD-negative women carrying a RhD-negative fetus, although this may lead to an increased risk of RhD sensitisations. Objectives: To systematically review the evidence on the diagnostic accuracy, clinical effectiveness and implementation of high-throughput NIPT and to develop a cost-effectiveness model. Methods: We searched MEDLINE and other databases, from inception to February 2016, for studies of high-throughput NIPT free-cell fetal deoxyribonucleic acid (DNA) tests of maternal plasma to determine fetal RhD status in RhD-negative pregnant women who were not known to be sensitised to the RhD antigen. Study quality was assessed with the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) and A Cochrane Risk of Bias Assessment Tool: for Non-Randomised Studies of Interventions (ACROBAT-NRSI). Summary estimates of false-positive rates (FPRs) and false-negative rates (FNRs) were calculated using bivariate models. Clinical effectiveness evidence was used to conduct a simulation study. We developed a de novo probabilistic decision tree-based cohort model that considered four alternative ways in which the results of NIPT could guide the use of anti-D immunoglobulin antenatally and post partum. Sensitivity analyses (SAs) were conducted to address key uncertainties and model assumptions. Results: Eight studies were included in the diagnostic accuracy review, seven studies were included in the clinical effectiveness review and 12 studies were included in the review of implementation. Meta-analyses included women mostly at or post 11 weeks’ gestation. The pooled FNR (women at risk of sensitisation) was 0.34% [95% confidence interval (CI) 0.15% to 0.76%] and the pooled FPR (women needlessly receiving anti-D) was 3.86% (95% CI 2.54% to 5.82%). SAs did not materially alter the overall results. Data on clinical outcomes, including sensitisation rates, were limited. Our simulation suggests that NIPT could substantially reduce unnecessary use of antenatal anti-D with only a small increase in the risk of sensitisation. All large implementation studies suggested that large-scale implementation of high-throughput NIPT was feasible. Seven cost-effectiveness studies were included in the review, which found that the potential for the use of NIPT to produce cost savings was dependent on the cost of the test. Our de novo model suggested that high-throughput NIPT is likely to be cost saving compared with the current practice of providing routine antenatal anti-D prophylaxis to all women who are RhD negative. The extent of the cost saving appeared to be sufficient to outweigh the small increase in sensitisations. However, the magnitude of the cost saving is highly sensitive to the cost of NIPT itself. Limitations: There was very limited evidence relating to the clinical effectiveness of high-throughput NIPT, with no evidence on potential adverse effects. The generalisability of the findings to non-white women and multiple pregnancies is unclear. Conclusions: High-throughput NIPT is sufficiently accurate to detect fetal RhD status in RhD-negative women from 11 weeks’ gestation and would considerably reduce unnecessary treatment with routine anti-D immunoglobulin, potentially resulting in cost savings of between £485,000 and £671,000 per 100,000 pregnancies if the cost of implementing NIPT is in line with that reflected in this evaluation. Future work: Further research on the diagnostic accuracy of NIPT in non-white women is needed. Study registration: This study is registered as PROSPERO CRD42015029497. Funding: The National Institute for Health Research Health Technology Assessment programme.https://doi.org/10.3310/hta22130 |